BST-236 Publications

Publications

ASH 2021 Presentation:

Aspacytarabine (BST-236) as Monotherapy is Safe, Well-tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

ASH 2020 Presentation:

Durable Remissions and Increased Overall Survival in AML Patients Unfit for Standard Intensive Chemotherapy Achieved with High-Dose Aspacytarabine (BST-236) Induction and Consolidation

ASH 2019 Oral Presentation:

Aspacytarabine (BST-236) is Safe and Efficacious as a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy

Blood Adv. 2019 Nov 26; 3(22): 3740–3749:

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

ASH 2018 Abstract: BST-236 Mechanism of Action

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

KOLs speak of BST-236:

Aspacytarabine (BST-236) as a potential new frontline therapy option for patients with AML that are unfit for intensive chemotherapy

An AML Global Portal interview of Dr. Selina Luger during ASH 2019